TY - JOUR
T1 - Experimental approaches
T2 - dietary and hormone therapy
AU - Jeppesen, P B
AU - Mortensen, P B
PY - 2003/12
Y1 - 2003/12
N2 - Patients who suffer from intestinal failure depend on parenteral support to maintain nutritional equilibrium. In this chapter, recommendations for evaluation the absorptive capacity of patients with intestinal failure are defined, and the evidence and magnitude of the effect of dietary and hormone therapy is given. Regarding dietary advice, the effects of employment of diets with various carbohydrate:fat ratios in short-bowel syndrome (SBS) patients with and without a preserved colon is presented. Focus has been placed on the use of growth hormone but also on the use of a novel intestinotrophic hormone, glucagon-like peptide 2, in the promotion of intestinal adaptation in SBS patients. Overall, the ultimate aim in the treatment of SBS patients is to optimize remnant intestinal function, thereby eliminating the need for parenteral support and improving quality of life in these patients.
AB - Patients who suffer from intestinal failure depend on parenteral support to maintain nutritional equilibrium. In this chapter, recommendations for evaluation the absorptive capacity of patients with intestinal failure are defined, and the evidence and magnitude of the effect of dietary and hormone therapy is given. Regarding dietary advice, the effects of employment of diets with various carbohydrate:fat ratios in short-bowel syndrome (SBS) patients with and without a preserved colon is presented. Focus has been placed on the use of growth hormone but also on the use of a novel intestinotrophic hormone, glucagon-like peptide 2, in the promotion of intestinal adaptation in SBS patients. Overall, the ultimate aim in the treatment of SBS patients is to optimize remnant intestinal function, thereby eliminating the need for parenteral support and improving quality of life in these patients.
KW - Gastrointestinal Agents/administration & dosage
KW - Glucagon-Like Peptide 2
KW - Glucagon-Like Peptides
KW - Growth Hormone/administration & dosage
KW - Humans
KW - Intestinal Absorption
KW - Jejunostomy
KW - Peptide Fragments/administration & dosage
KW - Short Bowel Syndrome/diet therapy
U2 - 10.1016/s1521-6918(03)00080-5
DO - 10.1016/s1521-6918(03)00080-5
M3 - Review
C2 - 14642864
SN - 1521-6918
VL - 17
SP - 1041
EP - 1054
JO - Best practice & research. Clinical gastroenterology
JF - Best practice & research. Clinical gastroenterology
IS - 6
ER -